Moderna has received regulatory approval from Health Canada to initiate the first human clinical trial of its Bundibugyo Ebola vaccine candidate. The phase 1 study will be conducted across three Canadian research centers and is designed to evaluate safety and immunogenicity in approximately 80 healthy adult volunteers. This milestone represents a significant advancement in expanding the company's vaccine portfolio against rare but potentially devastating filovirus threats, addressing an important gap in global health preparedness.

Summary auto-generated by AI from the original publisher's content. Editorial standards.